Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma

Osteosarcoma (OS) is the most common malignant bone tumor in adolescents, and the clinical treatment of OS mainly includes surgery, radiotherapy, and chemotherapy. However, the side effects of chemotherapy drugs are an issue that clinicians cannot ignore. Nanomedicine and drug delivery technologies play an important role in modern medicine. The development of nanomedicine has ushered in a new turning point in tumor treatment. With the emergence and development of nanoparticles, nanoparticle energy surfaces can be designed with different targeting effects. Not only that, nanoparticles have unique advantages in drug delivery. Nanoparticle delivery drugs can not only reduce the toxic side effects of chemotherapy drugs, but due to the enhanced permeability retention (EPR) properties of tumor cells, nanoparticles can survive longer in the tumor microenvironment and continuously release carriers to tumor cells. Preclinical studies have confirmed that nanoparticles can effectively delay tumor growth and improve the survival rate of OS patients. In this manuscript, we present the role of nanoparticles with different functions in the treatment of OS and look forward to the future treatment of improved nanoparticles in OS.

[1]  Zheng Zhao,et al.  Supercritical CO2-assisted fabrication of CM-PDA/SF/nHA nanofibrous scaffolds for bone regeneration and chemo-photothermal therapy against osteosarcoma. , 2023, Biomaterials science.

[2]  Jian Weng,et al.  pH-sensitive charge-conversion cinnamaldehyde polymeric prodrug micelles for effective targeted chemotherapy of osteosarcoma in vitro , 2023, Frontiers in Chemistry.

[3]  Ping Yuan,et al.  Multifunctional nanoparticles for the treatment and diagnosis of osteosarcoma. , 2023, Biomaterials advances.

[4]  W. Bi,et al.  Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma , 2023, Materials today. Bio.

[5]  Lei Xing,et al.  Hypoxia Inhibitor Combined with Chemotherapeutic Agents for Antitumor and Antimetastatic Efficacy against Osteosarcoma. , 2023, Molecular pharmaceutics.

[6]  Dinglin Zhang,et al.  Phytic acid-modified manganese dioxide nanoparticles oligomer for magnetic resonance imaging and targeting therapy of osteosarcoma , 2023, Drug delivery.

[7]  Yingying Jiang,et al.  Enhanced mild-temperature photothermal therapy by pyroptosis-boosted ATP deprivation with biodegradable nanoformulation , 2023, Journal of Nanobiotechnology.

[8]  GuanNing Shang,et al.  Targeted therapy for osteosarcoma: a review , 2023, Journal of Cancer Research and Clinical Oncology.

[9]  Jinlan Jiang,et al.  Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA , 2023, Frontiers in Oncology.

[10]  Changfeng Fu,et al.  Biomaterials delivery strategies to repair degenerated intervertebral discs by regulating the inflammatory microenvironment , 2023, Frontiers in Immunology.

[11]  M. Raucci,et al.  ROS-Generating Hyaluronic Acid-Modified Zirconium Dioxide-Acetylacetonate Nanoparticles as a Theranostic Platform for the Treatment of Osteosarcoma , 2022, Nanomaterials.

[12]  Jie Peng,et al.  Mechanism and Role of Endoplasmic Reticulum Stress in Osteosarcoma , 2022, Biomolecules.

[13]  S. Gierlotka,et al.  Co-Delivery System of Curcumin and Colchicine Using Functionalized Mesoporous Silica Nanoparticles Promotes Anticancer and Apoptosis Effects , 2022, Pharmaceutics.

[14]  Xue-Dong Li,et al.  Dioscin induces osteosarcoma cell apoptosis by upregulating ROS‐mediated P38 MAPK signaling , 2022, Drug development research.

[15]  X. Lan,et al.  Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy , 2022, Pharmaceutical Research.

[16]  Shun-Fa Yang,et al.  Curcumin in human osteosarcoma: from analogs to carriers. , 2022, Drug discovery today.

[17]  Yuehua Wu,et al.  Activation of Dynamin-Related Protein 1 and Induction of Mitochondrial Apoptosis by Exosome-Rifampicin Nanoparticles Exerts Anti-Osteosarcoma Effect , 2022, International journal of nanomedicine.

[18]  Jiawei Fan,et al.  Engineered nanomaterials trigger abscopal effect in immunotherapy of metastatic cancers , 2022, Frontiers in Bioengineering and Biotechnology.

[19]  Chang-feng Fu,et al.  Application of mesenchymal stem cell-derived exosomes from different sources in intervertebral disc degeneration , 2022, Frontiers in Bioengineering and Biotechnology.

[20]  Xiaojiao Du,et al.  Self-Amplified Chain-Shattering Cinnamaldehyde-Based Poly(thioacetal) Boosts Cancer Chemo-Immunotherapy. , 2022, Acta biomaterialia.

[21]  N. Zhang,et al.  Developing a Versatile Multiscale Therapeutic Platform for Osteosarcoma Synergistic Photothermo-Chemotherapy with Effective Osteogenicity and Antibacterial Capability. , 2022, ACS applied materials & interfaces.

[22]  Z. Shao,et al.  Targeted Delivery of PD‐L1‐Derived Phosphorylation‐Mimicking Peptides by Engineered Biomimetic Nanovesicles to Enhance Osteosarcoma Treatment , 2022, Advanced healthcare materials.

[23]  N. Artzi,et al.  Localized nanoparticle-mediated delivery of miR-29b normalises the dysregulation of bone homeostasis caused by osteosarcoma whilst simultaneously inhibiting tumour growth , 2022, bioRxiv.

[24]  Yuehong Li,et al.  Engineered bone cement trigger bone defect regeneration , 2022, Frontiers in Materials.

[25]  K. Hoang,et al.  Site-selective modification of metallic nanoparticles. , 2022, Chemical communications.

[26]  X. Yang,et al.  A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles , 2022, International journal of nanomedicine.

[27]  P. Hwu,et al.  Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. , 2022, The Lancet. Oncology.

[28]  Guannan Zhang,et al.  Multifunctional mesoporous silica nanoparticles for pH-response and photothermy enhanced osteosarcoma therapy. , 2022, Colloids and surfaces. B, Biointerfaces.

[29]  Yan Xu,et al.  Therapeutic Effects of Zoledronic Acid-Loaded Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticles on Osteosarcoma , 2022, Frontiers in Bioengineering and Biotechnology.

[30]  Yongqiang Dong,et al.  Bone tumors effective therapy through functionalized hydrogels: current developments and future expectations , 2022, Drug delivery.

[31]  X. Liu,et al.  Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating β-catenin via HIF-1α/BNIP3/LC3B-mediated mitophagy pathway , 2022, Bioactive materials.

[32]  Nikolas J. Wilhelm,et al.  Development and evaluation of machine learning models based on X-ray radiomics for the classification and differentiation of malignant and benign bone tumors , 2022, European Radiology.

[33]  Fei Jia,et al.  Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway , 2022, Oxidative medicine and cellular longevity.

[34]  Xuan Zeng,et al.  Multifunctional liquid metal-based nanoparticles with glycolysis and mitochondrial metabolism inhibition for tumor photothermal therapy. , 2022, Biomaterials.

[35]  Feng Xu,et al.  Biomaterials delivery strategies to repair spinal cord injury by modulating macrophage phenotypes , 2022, Journal of tissue engineering.

[36]  Chuanglong He,et al.  Tumor cell membrane-camouflaged responsive nanoparticles enable MRI-guided immuno-chemodynamic therapy of orthotopic osteosarcoma , 2022, Bioactive materials.

[37]  C. Sergi.  Targeting the ‘garbage-bin’ to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU , 2021, Bioscience Reports.

[38]  C. Sergi.  HDAC6 inhibitor WT161 performs antitumor effect on osteosarcoma and synergistically interacts with 5-FU. , 2021, Bioscience reports.

[39]  Qianhua Feng,et al.  Cascade catalytic nanoplatform based on ions interference strategy for calcium overload therapy and ferroptosis. , 2021, International journal of pharmaceutics.

[40]  Jun Huang,et al.  Zirconia-Based Solid Acid Catalysts for Biomass Conversion , 2021 .

[41]  H. Jo,et al.  Delivery of Anti‐microRNA‐712 to Inflamed Endothelial Cells Using Poly(β‐amino ester) Nanoparticles Conjugated with VCAM‐1 Targeting Peptide , 2021, Advanced healthcare materials.

[42]  M. Donadelli,et al.  Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons , 2021, Journal of experimental & clinical cancer research : CR.

[43]  Jie Huang,et al.  Marein ameliorates Ang II/hypoxia‐induced abnormal glucolipid metabolism by modulating the HIF‐1α/PPARα/γ pathway in H9c2 cells , 2020, Drug development research.

[44]  Jinlan Jiang,et al.  Polydopamine Nanoparticles Camouflaged by Stem Cell Membranes for Synergistic Chemo-Photothermal Therapy of Malignant Bone Tumors , 2020, International journal of nanomedicine.

[45]  Ya Zhang,et al.  Targeting the Wnt/β-catenin signaling pathway in cancer , 2020, Journal of Hematology & Oncology.

[46]  Runlan Luo,et al.  Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review , 2020, BMC Cancer.

[47]  Jinyong Luo,et al.  Cinnamaldehyde Inhibits the Function of Osteosarcoma by Suppressing the Wnt/β-Catenin and PI3K/Akt Signaling Pathways , 2020, Drug design, development and therapy.

[48]  Kai Sun,et al.  Mitophagy in degenerative joint diseases , 2020, Autophagy.

[49]  M. Gutierrez,et al.  The enzymatic poly(gallic acid) reduces pro-inflammatory cytokines in vitro, a potential application in inflammatory diseases , 2020, Inflammation.

[50]  L. Claude,et al.  Osteosarcoma , 2019, Definitions.

[51]  Q. Zheng,et al.  The Role of Autophagy and Mitophagy in Bone Metabolic Disorders , 2020, International journal of biological sciences.

[52]  Shengmin Zhang,et al.  Hierarchically constructed selenium-doped bone-mimetic nanoparticles promote ROS-mediated autophagy and apoptosis for bone tumor inhibition. , 2020, Biomaterials.

[53]  Deling Kong,et al.  Cascade of reactive oxygen species generation by polyprodrug for combinational photodynamic therapy. , 2020, Biomaterials.

[54]  F. Verrecchia,et al.  The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem , 2020, Cells.

[55]  Tao Chen,et al.  Andrographolide induces apoptosis in human osteosarcoma cells via the ROS/JNK pathway , 2020, International journal of oncology.

[56]  Thanh Loc Nguyen,et al.  Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold. , 2020, Biomaterials.

[57]  O. Shaker,et al.  Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles , 2020, Cancers.

[58]  J. Ji,et al.  Surface Charge Switchable Supramolecular Nanocarriers for Nitric Oxide Synergistic Photodynamic Eradication of Biofilms. , 2019, ACS nano.

[59]  Wei Yang,et al.  Acridine Orange Encapsulated Mesoporous Manganese Dioxide Nanoparticles to Enhance Radiotherapy. , 2019, Bioconjugate chemistry.

[60]  J. Ai,et al.  Natural Biomacromolecule based Composite Scaffolds from Silk Fibroin, Gelatin and Chitosan toward Tissue Engineering Applications. , 2019, International journal of biological macromolecules.

[61]  Sheng-lin Wang,et al.  A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro , 2019, International journal of nanomedicine.

[62]  Chao Zhang,et al.  Lung metastases at the initial diagnosis of high-grade osteosarcoma: prevalence, risk factors and prognostic factors. A large population-based cohort study , 2019, Sao Paulo medical journal = Revista paulista de medicina.

[63]  S. Shojaosadati,et al.  Aptamer functionalized curcumin-loaded human serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer cells. , 2019, International journal of biological macromolecules.

[64]  P. Lara,et al.  Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies. , 2019, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[65]  Ke Chen,et al.  Bioinspired Interfacial Chelating-like Reinforcement Strategy toward Mechanically Enhanced Lamellar Materials. , 2018, ACS nano.

[66]  Qinfei Ke,et al.  pH-responsive mesoporous ZSM-5 zeolites/chitosan core-shell nanodisks loaded with doxorubicin against osteosarcoma. , 2018, Materials science & engineering. C, Materials for biological applications.

[67]  Robin A Nadar,et al.  Bisphosphonate‐Functionalized Imaging Agents, Anti‐Tumor Agents and Nanocarriers for Treatment of Bone Cancer , 2017, Advanced healthcare materials.

[68]  Xiaodong Zhou,et al.  MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma , 2017, Cellular Physiology and Biochemistry.

[69]  F. Verrecchia,et al.  TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression , 2016, Journal of clinical medicine.

[70]  W. Murphy,et al.  Orthosilicic acid, Si(OH)4, stimulates osteoblast differentiation in vitro by upregulating miR-146a to antagonize NF-κB activation. , 2016, Acta biomaterialia.

[71]  P. Steinmann,et al.  Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy , 2016, Infectious Diseases of Poverty.

[72]  Hongbo Fang,et al.  RecQL4 regulates autophagy and apoptosis in U2OS cells. , 2016, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[73]  Fa-Ming Chen,et al.  Advancing biomaterials of human origin for tissue engineering. , 2016, Progress in polymer science.

[74]  P. Meltzer,et al.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  E. Álava,et al.  Bone microenvironment signals in osteosarcoma development , 2015, Cellular and Molecular Life Sciences.

[76]  Lei-Sheng Jiang,et al.  Hypoxia facilitates the survival of nucleus pulposus cells in serum deprivation by down-regulating excessive autophagy through restricting ROS generation. , 2015, The international journal of biochemistry & cell biology.

[77]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[78]  M. Lamas,et al.  Modified β-Cyclodextrin Inclusion Complex to Improve the Physicochemical Properties of Albendazole. Complete In Vitro Evaluation and Characterization , 2014, PloS one.

[79]  L. Shi,et al.  Synthesis, antibacterial activity, antibacterial mechanism and food applications of ZnO nanoparticles: a review , 2014, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[80]  Chunying Chen,et al.  Near‐Infrared Light‐Mediated Nanoplatforms for Cancer Thermo‐Chemotherapy and Optical Imaging , 2013, Advanced materials.

[81]  Eric C. Carnes,et al.  Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. , 2013, Accounts of chemical research.

[82]  L. Qin,et al.  Targeting the osteosarcoma cancer stem cell , 2010, Journal of orthopaedic surgery and research.

[83]  Lisa Wang,et al.  Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. , 2010, Biochemical and biophysical research communications.

[84]  Guido Kroemer,et al.  Self-eating and self-killing: crosstalk between autophagy and apoptosis , 2007, Nature Reviews Molecular Cell Biology.

[85]  Deok-Chun Yang,et al.  Expression and RNA interference-induced silencing of the dammarenediol synthase gene in Panax ginseng. , 2006, Plant & cell physiology.

[86]  K. Maruyama,et al.  Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer , 2002, International journal of cancer.

[87]  G. Wesolowski,et al.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[88]  J. Sung,et al.  Main ginseng saponin metabolites formed by intestinal bacteria. , 1996, Planta medica.

[89]  N Maggi,et al.  Rifampicin: a new orally active rifamycin. , 1966, Chemotherapy.

[90]  Hongbo Fang,et al.  Draft 1 Title : RecQL 4 regulates autophagy and apoptosis in U 2 OS cells , 2016 .

[91]  داوملا ةسدنھ.  Zinc oxide , 2015, Reactions Weekly.

[92]  S. Ferrari,et al.  Increased osteoclast activity is associated with aggressiveness of osteosarcoma. , 2008, International journal of oncology.

[93]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[94]  D. Maurici,et al.  Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma , 2005, Journal of Cancer Research and Clinical Oncology.